specific fetal and maternal risks. The choice of the anticoagulant regime for mechanical heart valve thrombosis should be made by balancing 2 risksmaternal morbidity and maternal mortality-from thromboembolic complications and fetal loss and embryopathy. The risk of valve thrombosis appears to be lowest with the use of oral anticoagulants throughout pregnancy (4%); however, this increases the risk of fetal embryopathy in 6.4% of live births. Substituting oral anticoagulants with heparin reduces the risk of fetopathic effects but increases the risk of thromboembolic complications. 1 A life-threatening complication of the therapy with heparin is heparin-induced thrombocytopenia type II (HIT). Heparin-induced thrombocytopenia type II is a prothrombotic condition that is associated with increased in vivo thrombin generation (as evidenced by the presence of elevated levels of thrombin-antithrombin complexes) and thus can be considered an acquired, hypercoagulability syndrome. 3 Heparin-induced thrombocytopenia type II, P regnancy in women with mechanical heart valves is not benign and carries a significant risk of maternal mortality of 1% to 4%. 1,2 Therapeutic anticoagulation for the prevention of thromboembolism is required throughout pregnancy in women with mechanical valve replacements, because pregnancy in women with mechanical prosthetic valves is associated with a high risk of thromboembolism, ranging from 4% to 25% despite adequate anticoagulation. 1 The anticoagulants currently available include coumarin derivates, heparin, and heparin-like compounds, as well as direct thrombin inhibitors. The various therapeutic options available have their own Anticoagulant therapy with heparin for the prevention of thromboembolism in pregnant women with prosthetic heart valves is associated with an increased risk to the mother and/or the fetus. A life-threatening complication of the therapy with heparin is heparininduced thrombocytopenia type II (HIT). danaparoid has not yet been reported to be safe and effective for this indication. This study reports on a 26-year-old woman with tricuspidal valve prosthesis and a 37-yearold woman with a St. Jude Medical mitral valve prosthesis who were anticoagulated with danaparoid during pregnancy because of HIT. Anti-Xa levels were between 0.6 and 1.2 IU/mL during pregnancy with target levels of 1.0 IU/mL. Cesarean section was performed at anti-Xa levels of 0.3 and 0.7 IU/mL. One woman developed a placental hematoma at the 32nd week of gestation, which did not increase over the following week. Both patients delivered healthy boys. Heparin-induced thrombocytopenia in pregnant women with prosthetic heart valve can be successfully managed with danaparoid.
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Keywords: HIT type II; pregnancy; mechanical heart valve; danaparoid with recovery of platelet counts to normal levels within days or weeks, and disappearance of the pathogenic HIT antibodies within weeks or a few months. Thus, there is important potential benefit (over the risk) of optimal antithrombotic management over the relatively brief period of the patient's life in which this paradoxical adverse event has occurred. When HIT is suspected, heparin must be immediately suspended and an alternative anticoagulant therapy should be initiated, because acute HIT is a strong, independent risk factor for venous and arterial thrombosis. 3 Although reports of pregnant or lactating women with prosthetic heart valves on treatment with oral anticoagulants are available, till date no data about pregnant women with prosthetic valves and HIT on treatment with danaparoid have been reported.
Danaparoid is a non-heparin, parenteral antithrombotic agent approved for use in HIT. It inhibits thrombin generation by accelerating inactivation of factor Xa by antithrombin and inhibits thrombin activity via both antithrombin and heparin cofactor II. Danaparoid also inhibits thrombin activation of factor IX. 4 Thus, danaparoid can control the rapid thrombin generation associated with HIT. 5, 6 Because coumadin and hirudin cross the placenta, danaparoid appears to be an alternative anticoagulant of choice during pregnancy in women with HIT (and former HIT) due to its low cross-reactivity with heparin-associated antibodies (3.2%) and its low placental permeability. 7 In this article, we report 2 cases of successful use of danaparoid in pregnant women with heart valve prosthesis and HIT and former HIT in a previous pregnancy.
Case 1: HIT Patient With Tricuspidal Valve Replacement Surgery
A 26-year-old primipara who underwent tricuspidal valve replacement surgery (St. Jude Medical 25 M) because of bacterial endocarditis at the age of 12 conceived under oral anticoagulation (phenprocoumon). Phenprocoumon was discontinued at the 5th week of gestation and full-dose intravenous unfractionated heparin therapy was given for 7 days, followed by subcutaneous unfractionated heparin every 12 hours with 6 hours activated partial thromboplastin time (aPTT) values 1.5 to 2.5 times the midrange normal. The platelet count was 202 × 10 3 /μL at the time of initiation of heparin therapy, 189 × 10 3 /μL on day 5, and 164 × 10 3 /μL on day 8. On day 12 after initiation of heparin therapy, the platelet count was 143 × 10 3 /μL. One day later, the diagnosis of HIT was supported by a strongly positive heparin/platelet factor 4 antibody titer determined by ELISA (absorption, 2.04; cut-off absorption, 0.594; Asserachrom HPIA Elisa, Diagnostica Stago, Parsippany, NJ). Unfractionated heparin therapy was discontinued and anticoagulation with danaparoid subcutaneously 3000 U twice a day (target anti-Xa level, 0.6 to 1.0 U/mL; danaparoid used as anti-Xa calibrator) was initiated and continued during pregnancy. Cross-reactivity to danaparoid was excluded by heparin-induced platelet activation assay (HIPA). The patient's platelet count increased progressively.
The patient showed a regular and uneventful course of pregnancy and a regular development of the fetus until 37 weeks of gestation. At this time, she developed preeclampsia with proteinuria (>1 g/L) and hypertension (blood pressure >140/90 mm Hg). A cesarean section was indicated. Danaparoid was discontinued (anti-Xa level, 1.05 U/mL) and after 43 hours when the anti-Xa level had dropped to 0.3 U/mL, the patient delivered a healthy boy (2630 g, 49 cm) by cesarean section without bleeding complications. Danaparoid was reinitiated intravenously (50 to 70 U/h) 2 hours after delivery for 1 day (anti-Xa level, 0.6 U/mL). The next day, full dose of danaparoid (120 U/h) was given intravenously (anti-Xa level, 1.0 U/mL) followed by gradual administration of phenprocoumon. Danaparoid was stopped at day 5 after cesarean section when the international normalized ratio (INR) was in therapeutic range (INR > 2.5). There were no thromboembolic or bleeding complications during pregnancy and puerperium.
Case 2: HIT Patient With History of Mitral Valve Stenosis
A 37-year-old woman (V gravida/ 0 para) with a history of mitral valve stenosis due to previous endocarditis who has a St. Jude Medical mitral-valve prosthesis since 1989 conceived under oral anticoagulation. Because of HIT with a thrombosis of the valve prosthesis on day 11 under full-dose unfractionated heparin in a previous pregnancy in 1998, phenprocoumon was discontinued at the 5th week of gestation and anticoagulation with danaparoid subcutaneously 3750 U twice a day (target anti-Xa level, 0.9 to 1.2 U/mL) was initiated. HIT was confirmed by a positive PF4/heparin antibody (ELISA) and a drop in platelet count from 260 × 10 3 /μL at the time of initiation of heparin, to 212 × 10 3 /μL on day 3, 189 × 10 3 /μL on day 5, 154 × 10 3 /μL on day 7, and to 109 × 10 3 /μL on day 9 of heparin therapy.
Two weekly controls of the anti-Xa inhibition were performed. The woman was examined by transthoracic echocardiography every 4 weeks to exclude a valve thrombosis or valve insufficiency. The followup showed an uneventful course of pregnancy and a regular development of the fetus until the 32nd week of gestation. At this time the woman presented with a placental hematoma (5 × 1 cm), which did not increase on continuing danaparoid anticoagulation over the following week. Because of increasing cardiac insufficiency in the 33rd week of gestation, a cesarean section was performed when the anti-Xa level had dropped to 0.7 U/mL after discontinuation of danaparoid. The woman delivered a healthy boy (1495 g, 43 cm). There were no bleeding complications, so danaparoid was reinitiated subcutaneously 4 hours after delivery (anti-Xa level, 1.0 U/mL) followed by gradual administration of phenprocoumon the night after cesarean section. Danaparoid was stopped at day 6 after cesarean section when the INR was in the therapeutic range (INR > 2.5).
Discussion
Treatment alternatives for pregnant women with heart valve prosthesis and HIT, for example, former HIT, are limited. If HIT is suspected, heparin treatment has to be stopped immediately and an alternative anticoagulation should be started. Danaparoid does not appear to cross the placenta, 8 and thus should be safe for management of pregnant patients with HIT and a high risk of thrombosis. However, the efficacy and safety of danaparoid treatment in this clinical setting is not proven.
Current treatment regimens of danaparoid are related to plasma anti-Xa activity responses because this is the most convenient plasma response to measure. However, the half-life of antithrombotic activity correlates closely with that of thrombin generation inhibition (both about 7 hours). 9, 10 Lack of plasma anti-Xa activity monitoring does not appear to have had adverse clinical consequences despite recommendations to monitor certain patients-pediatric, low or high body weight, and severe or end-stage renal failure. Although anti-Xa activity correlates poorly with bleeding or thrombotic events, 11 withinpatient checking for accumulation of anticoagulant activity that might lead to bleeding remains recommended in patients of low body weight or with severe or end-stage renal failure, and to ensure an adequate plasma response in patients of body weight >90 kg. These recommendations are now mentioned in national authorizations of marketing for danaparoid. We would also recommend checking plasma anti-Xa activity in monthly intervals during pregnancy.
Treatment failures have been reported for the use of low molecular weight heparin in pregnant women with prosthetic heart valves. [12] [13] [14] [15] For this reason, low molecular weight heparin throughout pregnancy in doses adjusted to keep a 4-hour postinjection anti-Xa heparin level at approximately 1.0 to 1.2 U/mL is recommended. 16 In both women described in our case report, plasma anti-Xa activity responses were well above the recommended target range of 0.6 to 1.0 U/mL, which might have facilitated the hematoma formation in case 2. Basically it shows how safe danaparoid is since despite the high anti-Xa levels, the hematoma did not increase during continued danaparoid treatment. In addition, the plasma anti-Xa level for case 2 was much higher at operation than for case 1; yet again there was no bleeding complication. As pointed out, 17 a median interval of 12 hours (range 4 to 24 hours) for vaginal delivery and median 24 hours (range 0 to 48 hours) for cesarean section from the last danaparoid dose is usually sufficient (1 patient underwent cesarean section while still on danaparoid because the surgeon did not know she was on it and there was no problem). Case 2 also showed that cesarean section was performed at a plasma anti-Xa level of 0.7 U/mL.
In conclusion, in pregnant women with prosthetic heart valves and HIT and former HIT, danaparoid seems to be an alternative anticoagulant of choice.
